Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088049 · ClinicalTrials.gov registry record · Phase 4
Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 560
- Enrollment target
NCT00088049: Completed Phase 4 study, sponsored by Eli Lilly and Company.
NCT00088049 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 560 participants, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00088049, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 560 participants
- Enrollment target
Study Summary
The purpose of the protocol is to evaluate the efficacy of olanzapine compared with Aripiprazole in patients with schizophrenia.
Interventions
- DRUG Olanzapine
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 560 participants |
| Start Date | 2003-10 |
| Est. Completion | 2007-07 |
| Phase | Phase 4 |
What the finished NCT00088049 record still lists
NCT00088049 is an interventional study that assigns participants to a tested intervention. The registered 560 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Olanzapine is the first listed.
NCT00088049 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00088049 about?
NCT00088049 is a clinical study titled "Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia". The purpose of the protocol is to evaluate the efficacy of olanzapine compared with Aripiprazole in patients with schizophrenia.
What is the current status of trial NCT00088049?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 560 participants. The study started on 2003-10. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00088049?
The interventions under investigation include: Olanzapine (DRUG), Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00088049?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00088049's enrollment target sits among peer trials
560 152nd of 2000 higher than 1,849 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04661358 · 560 participants · Phase 3
Fenofibrate for Prevention of DR Worsening
- NCT05473871 · 560 participants · NA
Enhancing Capacity in Churches to Implement PA Programs
- NCT06001541 · 560 participants · NA
Web-based Program to Improve Self-management Among Veterans-caregiver Dyads
- NCT06246916 · 560 participants · Phase 3
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia